Surgical Science Sweden Ab · OMXSTO:SUS

Surgical Science Sweden Ab — Q4 2025 Earnings Presentation

10 slides from Surgical Science Sweden Ab's earnings presentation, Feb 19, 2026

  1. Slide 1: Presentation of Year-end Report 2025

    Presentation of Year-end Report 2025 ©2025 Surgical Science. | All rights reserved.

  2. Slide 2: CEO comments – Q4 2025

    CEO comments – Q4 2025 ▪ In Q4, Surgical Science continued to take steps in the right direction ▫ Net sales of SEKm 269, 7% growth. 15% growth adjusted for FX ▫ Adjusted EBIT at 17%, in line with financial targets ▪ Mixed performance in Educational products with 4% growth ▫ Continued high activity i

  3. Slide 3: Q4: Profitability in line with financial targets

    Q4: Profitability in line with financial targets Q4: SEKm ▪ Net sales up 7% to SEKm 268.9 (251.5). In local currencies up 15%. SEKm 14.2 from IU. ▪ Educational Products up 4% (-8% excl IU). Regions: Europe +4%, Asia -21%, Americas +43%. ▪ Industry/OEM up 10%. License revenues up 21%, SEKm 92.3 (76.4

  4. Slide 4: Revenue streams

    Revenue streams SEKm ▪ License rev’s: 34% (30) of total revenues. Intuitive sales strong both in terms of dV5 and older generations. Larger batch order from another robotic customer. ▪ Simulator sales down 12%. ▪ Continued strong development rev’s. Consists of both robotics’ projects and sales of si

  5. Slide 5: Costs and EBIT margin Q4 2025

    Costs and EBIT margin Q4 2025 ▪ Gross margin 66% (68). Higher license revenues positive, but currency and inclusion of IU negative effect. Costs/margin as a percentage of sales ▪ Sales: 17% (20) of sales. SEKm 3 in tariffs on simulators from non-US production units. Operating margin 15% (16) ▪ Admin

  6. Slide 6: Organization

    Organization No of employees at end of period: 313 (274) Men 226 (199) Women 87 (75) Israel 152 (138) Sweden 68 (64) USA 44 (54) UK 28 (1) Other 21 (17) * Offices / Development sites * Other: Primarily Germany and China. 5

  7. Slide 7: Adjusted EBIT*

    Adjusted EBIT* Q4: ▪ Adjusted EBIT SEKm 45.7. Adjusted for restructuring costs SEKm 48.4 (45.3), margin 18% (18). FY2025: ▪ Adjusted EBIT SEKm 91.8. Adjusted for acquisition and restructuring costs SEKm 122.4 (168.7), margin 12% (19). *Excluding acquisition and restructuring costs related to IU in Q

  8. Slide 8: Finance net and taxes

    Finance net and taxes Q4: ▪ Finance net for the quarter SEKm 2.4 (0.3). Interest on bank balances, revaluation of internal loans and IFRS 16 effect. ▪ Tax expense for the quarter SEKm -9.2 (-3.2). ▪ Net result for the quarter SEKm 33.3 (36.3). FY 2025: ▪ Finance net for the year SEKm 31.3 (13.8). In

  9. Slide 9: Cash flow

    Cash flow SEKm 800 18% ▪ Cash flow from operating activities SEKm 72.9 (56.7). Change in working capital 700 16% SEKm -3.0 (-2.2). Inventory unchanged, 600 14% A/R decreased. 12% 500 ▪ Cash flow from investing activities SEKm 10% -15.1 (-12.1) mainly investments in 400 8% development costs. SEKm 3.2

  10. Slide 10: Thank you

    Thank you Find out more at: www.surgicalscience.com ©2025 Surgical Science. | All rights reserved.

Surgical Science Sweden — Q4 2025 Earnings Presentation on 6ix